An anti-cancer drug succeeds in the first phase of clinical testing
Successfully completed the first phase of clinical testing.
According to the Russian "TASS" agency, the developers of the Russian gene therapy drug against cancer, AntionkoRAN-M, have completed the first phase of clinical tests, confirming its safety. This was reported by the press service of the Russian National Technology Initiative platform.
It is noteworthy that "AntionkoRAN-M" is the first Russian drug for non-viral gene therapy against cancer, which received a license from the Ministry of Health to conduct clinical tests. The tests included 13 patients between the ages of 30 and 78 years. The drug was developed by the company "Russian Biotechnology".
Maxim Kokcharov, founder of the Russian Biotechnology company, said: “The main goal of the first phase of clinical testing of the drug is to confirm the safety of the drugs for patients, and during the study, no serious negative phenomena were identified associated with the use of the drug AntionkoRAN-M in any of the patients.” In addition, a response to treatment was obtained in many patients even though they had undergone a large number of different treatment programs and had exhausted all possible treatment methods.
The active portion of the phase 1 studies lasted for two years. During this time, the developers of the drug confirmed its safety, chose the necessary dose and sequence of treatment, evaluated the distribution of the drug in the human body, and diagnosed patients with tumors with diseases such as skin cancer, breast cancer, chondrosarcoma, and others.
Kokcharov added, "All these classifications of patients need new types of treatments because doctors have a limited number of tools to combat them, and we have two new stages of research before we can put the drug on the market."
In the next stages of testing, scientists will evaluate the effectiveness of the drug in combating different types of tumors, as well as its effect on a wider group of patients. The company sent a package of documents to the Russian Ministry of Health to obtain permission to conduct clinical tests for the second phase.
Source: websites